<DOC>
	<DOCNO>NCT00100737</DOCNO>
	<brief_summary>The purpose study determine whether interleukin-2 give 3 time weekly 8 week combination rituximab effective safe compare rituximab give alone treatment follicular NHL subject never receive rituximab treatment refractory relapse previous chemotherapy .</brief_summary>
	<brief_title>Comparing Interleukin-2 ( IL-2 ) Combined With Rituximab ( Rituxan ) Rituximab Alone Subjects With Non-Hodgkin ’ Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>CD20+ follicular Bcell nonhodgkin ’ lymphoma least 1 site measurable disease . Previous treatment 1 4 prior chemotherapy regimen ECOG performance status great equal 2 Life expectancy great 18 week Meet safety lab requirement organ function test Prior treatment rituximab IL2 Prior radioimmunotherapy include Zevalin Bexxar 5 prior chemotherapy regimen Clinically significant cardiac disease , lung dysfunction , autoimmune disease , thyroid disease , active infection , unstable psychiatric condition , HIV infection . History allogenic bone marrow transplant Female subject pregnant breast feed Immunosuppressive therapy include corticosteroid investigational agent within 4 week prior plan start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>non-hodgkins lymphoma</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>rituximab</keyword>
	<keyword>CD20+ follicular B-cell non-hodgkins lymphoma ( grade I , II , III )</keyword>
</DOC>